恒瑞医药：瑞维鲁胺片获得《药物临床试验批准通知书》

Group 1 - The core point of the article is that Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of Ruvelimab tablets, indicating a significant step in its drug development process [1] - Heng Rui Medicine's revenue composition for the year 2024 is reported to be 89.37% from the pharmaceutical manufacturing sector and 10.63% from other businesses, highlighting the company's strong focus on its core operations [1] - As of the report, Heng Rui Medicine's market capitalization stands at 421.9 billion yuan, reflecting its substantial presence in the pharmaceutical industry [1]